Furthermore, we evaluated the salvage therapeutic efficacy of bevacizumab, a humanized monoclonal Ab against vascular endothelial growth factor (VEGF), on trastuzumab-refractory SCLC. Here, VEGFA is linked to small cell lung carcinoma.